儿童急性缺血性卒中溶栓治疗的资格评估
这项回顾性多中心观察性队列研究分析了2010至2019年间135例儿童(29天至17岁)的症状性急性缺血性卒中(AIS),发现无论诊断延迟与否,仅19%的AIS可能符合tPA治疗资格。研究还探讨了小血管AIS和脑肿瘤相关AIS的额外排除标准及结局。
要点
- 儿童症状性AIS中仅19%可能符合tPA治疗资格,81%因各种原因被排除。
- 符合tPA资格的AIS中50%未接受tPA即获得无残疾结局。
- 小血管AIS占39%,其中33%无额外溶栓禁忌,或可扩展tPA适应症。
核心结论
- 基于现行推荐,19%的儿童症状性AIS可能符合tPA治疗资格,无论诊断延迟与否。
- 部分小血管AIS患者可能为扩展tPA适应症提供机会。
研究设计与样本
- 回顾性、多中心、观察性队列研究,纳入2010年1月1日至2019年12月31日期间三家医院收治的29天至17岁症状性AIS儿童。
- 共135例患者,139次症状性AIS;中位年龄6岁,36%为女性,73%经急诊就诊,平均随访43个月,12%死亡。
主要发现
- 符合tPA资格的AIS中,急性神经影像显示大血管闭塞、单侧局灶性脑动脉病或颅外动脉夹层。
- 26次可能符合tPA的AIS中,13次(50%)未接受tPA即获得无残疾结局。
- 所有死亡均发生在被排除tPA的患者中,主要与基础疾病相关。
临床怎么用
- 临床评估儿童AIS时,应依据现行多国及2026年AHA指南判断tPA治疗资格,并注意诊断延迟以外的排除原因。
- 对于小血管AIS且无额外禁忌的患儿,可考虑个体化评估tPA治疗的潜在获益。
局限性
- 回顾性研究设计可能存在选择偏倚和信息偏倚。
- 样本量有限(135例患者,139次AIS),结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thrombolysis is infrequently delivered to children with acute ischemic strokes (AIS). We explored potential eligibility for treatment with tPA (tissue-type plasminogen activator) for pediatric AIS. METHODS: This retrospective, multicenter, observational, cohort study reviewed children aged 29 days to 17 years with symptomatic AIS identified via Children's Hospital Westmead, John Hunter Children's Hospital, and Sydney Children's Hospital between January 1, 2010, and December 31, 2019. Medical records were examined to evaluate eligibility for treatment with tPA based on established multinational and the 2026 American Heart Association guidelines, reasons for exclusion beyond delay to diagnosis, and long-term outcomes as pediatric modified Rankin Scale scores. We also explored additional exclusions and outcomes among children with small-vessel AIS and AIS in the context of brain tumors, who are currently excluded from tPA. RESULTS: A total of 135 patients with 139 symptomatic AIS were identified-median age, 6 years; 36% female patients; 73% presented via emergency departments; mean follow-up, 43 months; 12% deaths. Irrespective of delay to diagnosis, only 26 of 139 (19%) AIS were potentially eligible for treatment with tPA. Among patients potentially eligible for tPA, acute neuroimaging revealed large-vessel occlusions, unilateral focal cerebral arteriopathy, or extracranial dissections. Thirteen of 26 (50%) had nondisabled outcomes without tPA treatment. One hundred thirteen of 139 (81%) AIS were ineligible for treatment with tPA, irrespective of delay to diagnosis. All deaths occurred among patients excluded from tPA, predominantly related to underlying disorders. Fifty-four small-vessel AIS accounted for 39% of AIS. Eighteen (33%) had no additional ineligibilities to thrombolysis, among whom 10 had nondisabled outcomes without tPA. CONCLUSIONS: Based on current recommendations, 19% of symptomatic childhood AIS were potentially eligible for treatment with tPA, irrespective of delay to diagnosis. Selected patients with small-vessel AIS may offer an opportunity to extend the role of tPA. These observations may be relevant for optimizing pediatric stroke management strategies.
引用
- Briest RC, Bhatia KD, Miteff C, et al. Eligibility for Thrombolysis for Pediatric Acute Ischemic Stroke. Stroke. 2026. PMID: 42657473. doi:10.1161/STROKEAHA.125.054223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。